OraSure Technologies Resultados de beneficios anteriores

Pasado controles de criterios 1/6

Los beneficios de OraSure Technologies han disminuido a una tasa media anual de -0.7%, mientras que en la industria Medical Equipment los beneficios crecieron en un 13.5% anualmente. Los ingresos han ido creciendo a una tasa media de 26.1% al año. La rentabilidad financiera de OraSure Technologies es de 12.5%, y sus márgenes netos son de 13.2%.

Información clave

-0.7%

Tasa de crecimiento de los beneficios

-3.8%

Tasa de crecimiento del BPA

Crecimiento de la industria Medical Equipment	8.9%
Tasa de crecimiento de los ingresos	26.1%
Rentabilidad financiera	12.5%
Margen neto	13.2%
Próxima actualización de resultados	08 May 2024

Actualizaciones de resultados anteriores recientes

Recent updates

Lacklustre Performance Is Driving OraSure Technologies, Inc.'s (NASDAQ:OSUR) Low P/S

Apr 17

Earnings Beat: OraSure Technologies, Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Mar 01

Return Trends At OraSure Technologies (NASDAQ:OSUR) Aren't Appealing

Feb 29

OraSure Technologies, Inc.'s (NASDAQ:OSUR) Business And Shares Still Trailing The Industry

Dec 20

Returns On Capital At OraSure Technologies (NASDAQ:OSUR) Have Stalled

Nov 08

Industry Analysts Just Upgraded Their OraSure Technologies, Inc. (NASDAQ:OSUR) Revenue Forecasts By 14%

Aug 09

Analysts Have Just Cut Their OraSure Technologies, Inc. (NASDAQ:OSUR) Revenue Estimates By 12%

May 16

Return Trends At OraSure Technologies (NASDAQ:OSUR) Aren't Appealing

May 13

Party Time: Brokers Just Made Major Increases To Their OraSure Technologies, Inc. (NASDAQ:OSUR) Earnings Forecasts

Feb 17

Are OraSure Technologies, Inc. (NASDAQ:OSUR) Investors Paying Above The Intrinsic Value?

Jun 14

OraSure: Not So Sure With Softening Fundamentals, Fairly Priced At $2.54

Jun 10

OraSure Technologies: A Bet On What Used To Be

Mar 05

OraSure Technologies (NASDAQ:OSUR) May Have Issues Allocating Its Capital

Nov 11

The Bottom Fishing Club: OraSure Technologies

Oct 22

Desglose de ingresos y gastos
Beta

Cómo gana y gasta dinero OraSure Technologies. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).

Historial de beneficios e ingresos

NasdaqGS:OSUR Ingresos, gastos y beneficios (USD Millions)
Fecha	Ingresos	Beneficios	Gastos G+A	Gastos de I+D
31 Dec 23	405	54	92	33
30 Sep 23	453	49	101	35
30 Jun 23	480	43	111	36
31 Mar 23	475	29	115	38
31 Dec 22	387	-17	117	36
30 Sep 22	328	-43	118	37
30 Jun 22	265	-64	115	36
31 Mar 22	243	-47	107	34
31 Dec 21	234	-23	95	34
30 Sep 21	233	-11	89	36
30 Jun 21	227	5	80	35
31 Mar 21	199	-4	79	34
31 Dec 20	172	-15	77	31
30 Sep 20	158	-14	74	27
30 Jun 20	146	-2	72	23
31 Mar 20	156	13	67	21
31 Dec 19	155	17	65	20
30 Sep 19	150	25	73	18
30 Jun 19	159	20	70	17
31 Mar 19	161	19	69	17
31 Dec 18	182	20	69	16
30 Sep 18	177	17	57	16
30 Jun 18	174	15	57	15
31 Mar 18	174	16	58	14
31 Dec 17	166	31	58	13
30 Sep 17	145	31	60	10
30 Jun 17	135	31	59	10
31 Mar 17	126	30	57	10
31 Dec 16	123	20	58	10
30 Sep 16	125	17	58	11
30 Jun 16	123	12	61	10
31 Mar 16	122	11	62	10
31 Dec 15	120	8	61	11
30 Sep 15	116	1	63	12
30 Jun 15	114	1	61	13
31 Mar 15	110	1	62	12
31 Dec 14	106	-5	65	12
30 Sep 14	107	4	66	10
30 Jun 14	103	1	65	10
31 Mar 14	101	-7	67	9
31 Dec 13	99	-11	69	10
30 Sep 13	92	-23	68	11
30 Jun 13	90	-24	67	11

Ingresos de calidad: OSUR tiene un gran one-off loss de $21.4M impacto en sus últimos 12 meses de resultados financieros a 31st December, 2023.

Margen de beneficios creciente: OSUR pasó a ser rentable.

Análisis del flujo de caja libre vs. Beneficios

Análisis del crecimiento de los beneficios en el pasado

Tendencia de beneficios: Los beneficios de OSUR han disminuido en un 0.7% al año en los últimos 5 años.

Acelerando crecimiento: OSUR ha pasado a ser rentable en el último año, lo que dificulta la comparación de la tasa de crecimiento de los beneficios con su promedio de 5 años.

Beneficios vs. Industria: OSUR ha pasado a ser rentable en el último año, lo que es difícil comparar el crecimiento de sus beneficios en el último año con el de la industria Medical Equipment (3.3%).

OraSure Technologies Resultados de beneficios anteriores

Pasado controles de criterios 1/6

Información clave

Actualizaciones de resultados anteriores recientes

OraSure Technologies, Inc. Reports Impairment Charges for the Fourth Quarter Ended December 31, 2023

Full year 2023 earnings: EPS exceeds analyst expectations

OraSure Technologies, Inc. to Report Fiscal Year 2023 Results on Feb 27, 2024

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

OraSure Technologies, Inc. to Report Q3, 2023 Results on Nov 07, 2023

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Recent updates

Lacklustre Performance Is Driving OraSure Technologies, Inc.'s (NASDAQ:OSUR) Low P/S

New minor risk - Shareholder dilution

OraSure Technologies, Inc., Annual General Meeting, May 14, 2024

Earnings Beat: OraSure Technologies, Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

New minor risk - Earnings quality

OraSure Technologies, Inc. Reports Impairment Charges for the Fourth Quarter Ended December 31, 2023

Return Trends At OraSure Technologies (NASDAQ:OSUR) Aren't Appealing

Full year 2023 earnings: EPS exceeds analyst expectations

OraSure Technologies, Inc. to Report Fiscal Year 2023 Results on Feb 27, 2024

Chief Product Officer notifies of intention to sell stock

OraSure Technologies, Inc.'s (NASDAQ:OSUR) Business And Shares Still Trailing The Industry

Investor sentiment improves as stock rises 18%

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

OraSure Technologies, Inc. Provides Financial Guidance for the Fourth Quarter 2023

Returns On Capital At OraSure Technologies (NASDAQ:OSUR) Have Stalled

OraSure Technologies, Inc. to Report Q3, 2023 Results on Nov 07, 2023

Investor sentiment improves as stock rises 41%

Industry Analysts Just Upgraded Their OraSure Technologies, Inc. (NASDAQ:OSUR) Revenue Forecasts By 14%

New minor risk - Share price stability

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

OraSure Technologies, Inc. Provides Revenue Guidance for the Third Quarter of 2023

OraSure Technologies, Inc. to Report Q2, 2023 Results on Aug 03, 2023

OraSure Technologies, Inc. Announces Election of Robert W. McMahon to its Board of Directors, Effective July 31, 2023

Price target decreased by 7.2% to US$6.45

OraSure Technologies, Inc. Announces Study Concludes Self-Sampling Using Colli-Pee® Device for HPV Screening Is Both Cost Effective and Could Improve Patient Access

Investor sentiment improves as stock rises 17%

Chief Financial Officer recently bought US$493k worth of stock

Investor sentiment deteriorates as stock falls 22%

Analysts Have Just Cut Their OraSure Technologies, Inc. (NASDAQ:OSUR) Revenue Estimates By 12%

Return Trends At OraSure Technologies (NASDAQ:OSUR) Aren't Appealing

Price target increased by 13% to US$6.95

Orasure Technologies, Inc. Provides Earnings Guidance for the Second Quarter 2023

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

OraSure Technologies, Inc. to Report Q1, 2023 Results on May 10, 2023

Party Time: Brokers Just Made Major Increases To Their OraSure Technologies, Inc. (NASDAQ:OSUR) Earnings Forecasts

Price target increased by 8.0% to US$5.88

Full year 2022 earnings: EPS and revenues exceed analyst expectations

OraSure Technologies, Inc. Provides Revenue Guidance for the First Quarter of 2023

OraSure Technologies, Inc. to Report Q4, 2022 Results on Feb 14, 2023

We're Not Very Worried About OraSure Technologies' (NASDAQ:OSUR) Cash Burn Rate

Consensus estimates of losses per share improve by 69%

High number of new directors

OraSure Technologies, Inc. Announces Executive Changes

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

OraSure Technologies, Inc. Reports Goodwill and Long-Lived Assets Impairment Charges for the Third Quarter Ended September 30, 2022

Orasure Technologies Receives General Clearance for Its ORAcollect--Dx Device for over the Counter Use from the U.S. Food and Drug Administration

OraSure Technologies, Inc. Announces InteliSwab Covid-19 Rapid Test Now Available in Amazon’s Online Store

OraSure Technologies, Inc. to Report Q3, 2022 Results on Nov 08, 2022

OraSure wins $8.6M government contract for next-gen Ebola test

OraSure: Revenue Mix Continues To Present Risk

Independent Director recently bought US$200k worth of stock

Biden administration ending free at-home COVID tests due to lack of funding

Independent Chairman of the Board recently bought US$54k worth of stock

Consensus revenue estimates increase by 11%

OraSure Technologies, Inc. Announces CFO Changes

Is OraSure Technologies (NASDAQ:OSUR) In A Good Position To Invest In Growth?

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

OraSure Technologies, Inc. Provides Revenue Guidance for the Third Quarter of 2022

OraSure Technologies, Inc. to Report Q2, 2022 Results on Aug 09, 2022

OraSure Technologies, Inc. Announces Executive Changes

OraSure Technologies LaunchesNewProduct for Microbiome Researchers to Study DNA and RNA

OraSure Technologies, Inc.(NasdaqGS:OSUR) dropped from Russell 2000 Value-Defensive Index

Are OraSure Technologies, Inc. (NASDAQ:OSUR) Investors Paying Above The Intrinsic Value?

OraSure Technologies, Inc. Announces Resignation of Agnieszka M. Gallagher as Executive Vice President, General Counsel and Chief Compliance Officer, Effective June 25, 2022

OraSure: Not So Sure With Softening Fundamentals, Fairly Priced At $2.54

OraSure Technologies, Inc. Appoints Carrie Eglinton Manner as President, Effective June 4, 2022

OraSure Technologies, Inc. Announces That Its InteliSwab® Covid-19 Rapid Tests Detect the Omicron BA.2, BA.2.12.1, BA.3 and BA.5 Subvariants

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Price target decreased to US$10.90

Desglose de ingresos y gastos
Beta